Table 1 Details of transcatheter thrombolysis therapy
No. of patients | location of thrombosis | Route of thrombolysis | Days of SMA thrombolysis | Agent and dose of SMA thrombolysis | Days of SMV thrombolysis | Agent and dose of SMV thrombolysis | Total dose of thrombolytics | Days of thrombolytic infusion |
|---|---|---|---|---|---|---|---|---|
1 | PV + SPV + SMV | SMA (first) + PT (next) | 6 | Urokinase (3,200,000 IU) | 5 | Urokinase (2,800,000 IU) | Urokinase (6,000,000 IU) | 11 |
2 | PV + SMV + IVC | SMA + PT | 3 | Urokinase (600,000 IU) | 7 | Urokinase (2,600,000 IU) | Urokinase (3,200,000 IU) | 7 |
3 | SMV | PT + SMA | 6 | urokinase (1,700,000 IU) | 6 | Urokinase (1,200,000 IU) | Urokinase (2,900,000 IU) | 6 |
4 | PV + SPV + SMV + IVC | SMA | 5 | Alteplase (60 mg) + urokinase (1,200,000 IU) | - | - | Alteplase (60 mg) + urokinase (1,200,000 IU) | 5 |
5 | PV + SMV + IVC | TI + SMA | 3 | Alteplase (10 mg) + urokinase (600,000 IU) | 6 | Alteplase (110 mg) + urokinase (400,000 IU) | Alteplase (120 mg) + urokinase (1,000,000 IU) | 6 |
6 | PV + SPV + SMV | PT + SMA | 5 | Alteplase (30 mg) | 5 | Alteplase (50 mg) | Alteplase (80 mg) | 5 |